Publications by authors named "Anna Hagenhoff"
Article Synopsis
- Mesenchymal stem cells (MSCs) engineered to express a sodium iodide symporter (NIS) gene can home in on solid tumors, particularly in hypoxic conditions often found in tumors like hepatocellular carcinoma (HCC).
- Under hypoxia, these engineered MSCs exhibit strong transgene induction, resulting in effective radioiodide uptake and significant accumulation of the NIS in tumors, confirmed by imaging techniques such as scintigraphy and PET.
- Treating mice with NIS-transfected MSCs and therapeutic doses of radioiodine (131I) showed delayed tumor growth, reduced blood supply to tumors, and improved survival, highlighting the effectiveness of targeting tumor hypoxia for cancer therapy.
Harnessing mesenchymal stem cell homing as an anticancer therapy.
Expert Opin Biol Ther
September 2016
Introduction: Mesenchymal stromal cells (MSCs) are non-hematopoietic progenitor cells that have been exploited as vehicles for cell-based cancer therapy. The general approach is based on the innate potential of adoptively applied MSC to undergo facilitated recruitment to malignant tissue. MSC from different tissue sources have been engineered using a variety of therapy genes that have shown efficacy in solid tumor models.
View Article and Find Full Text PDF